News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TherapeuticsMD, Inc.  (TXMD) Receives Notice Of Allowance For Patent Covering Platform Technology Of Oral Combination Bioidentical 17ß-Estradiol And Progesterone


12/9/2013 10:17:22 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NYSE MKT:TXMD), a women’s healthcare company ("TherapeuticsMD" or the "Company"), announced today that it received a Notice of Allowance from the U.S. Patent and Trademark Office pertaining to its U.S. Patent Application 13/684,002 - "Natural Combination Hormone Replacement Formulations and Therapies." This Patent Application covers the Company’s platform technology TX 12-001-HR, its oral bioidentical 17ß-estradiol and progesterone combination drug candidate.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES